Second Genome Nominates Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD)

Company to unveil new preclinical data for SG-5-00455 at 17th Congress of European Crohn’s and Colitis Organization (ECCO) plenary session on February 18, 2022

Virtual key opinion leader (KOL) event hosted by Company on role of mucosal healing andPAI-1/2 in IBD to occur on Wednesday, February 23 at 12 p.m. EST

Excerpt from the Press Release:

BRISBANE, Calif., Feb. 10, 2022 /PRNewswire/ — Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, today announced that the Company will advance SG-5-00455, which targets plasminogen activator inhibitor (PAI)-1/2, as a development candidate for the treatment of inflammatory bowel disease (IBD). The Company will present new preclinical data on SG-5-00455 at the virtual 17th Congress of European Crohn’s and Colitis Organization (ECCO) on February 18, 2022.

“We are excited to be moving SG-5-00455, our development candidate for the treatment of IBD, one step closer to patients. With its PAI-1/2 inhibition mechanism of action, we are targeting a well validated pathway that has been shown to play an important role in the pathophysiology of IBD. We believe that direct modulation of tissue repair pathways has the potential to directly improve mucosal healing and drive superior therapeutic outcomes, including when combined with the current standard of care anti-inflammatory approaches,” said Karim Dabbagh, Ph.D., President and Chief Executive Officer of Second Genome. “This is an important milestone for Second Genome’s internal pipeline. We look forward to presenting new data at ECCO’22 and hosting our upcoming IBD KOL expert panel, both of which are occurring later this month, as we plan to file an investigational new drug (IND) application for SG-5-00455 in the second half of 2022.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release